Anlotinib alone or in combination with temozolomide in recurrent high-grade glioma: A retrospective study.

被引：0
|
作者：
Yang, Qun-ying
Guo, Cheng-Cheng
He, Zhenqiang
Lin, Fuhua
Zhang, Ji
Guo, Xiaoyu
Chen, Yinsheng
Jiang, Xiaobing
Ke, Chao
Chen, Zhongping
Mou, Yonggao
机构：
[1] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Neurosurg Neuro Oncol, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, Canc Ctr, Dept Neurosurg Neurooncol, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e14019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14019
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.
    Wang, Chao-Jie
    Yin, Ming-Mei
    Zhao, Zheng
    Zhang, Meng-Yi
    Zhao, Wei-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [12] Length of Thromboprophylaxis in Patients Operated on for a High-Grade Glioma: A Retrospective Study.
    Senders, Joeky T.
    Snijders, Tom J.
    van Essen, Max
    van Bentum, Gaby M.
    Seute, Tatjana
    de Vos, Filip Y.
    Smith, Timothy R.
    Robe, Pierre A.
    Broekman, Marike L. D.
    WORLD NEUROSURGERY, 2018, 115 : E723 - E730
  • [13] Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
    Verhoeff, J. J. C.
    Lavini, C.
    van Linde, M. E.
    Stalpers, L. J. A.
    Majoie, C. B. L. M.
    Reijneveld, J. C.
    van Furth, W. R.
    Richel, D. J.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1723 - 1727
  • [14] Phase II trial of temozolomide in children with recurrent high-grade glioma
    A. Ruggiero
    G. Cefalo
    M.L. Garré
    M. Massimino
    C. Colosimo
    G. Attinà
    I. Lazzareschi
    P. Maurizi
    V. Ridola
    G. Mazzarella
    M. Caldarelli
    C. Di Rocco
    E. Madon
    M.E. Abate
    A. Clerico
    A. Sandri
    R. Riccardi
    Journal of Neuro-Oncology, 2006, 77 : 89 - 94
  • [15] Phase II trial of temozolomide in children with recurrent high-grade glioma
    Ruggiero, A.
    Cefalo, G.
    Garre, M. L.
    Massimino, M.
    Colosimo, C.
    Attina, G.
    Lazzareschi, I.
    Maurizi, P.
    Ridola, V.
    Mazzarella, G.
    Caldarelli, M.
    Di Rocco, C.
    Madon, E.
    Abate, M. E.
    Clerico, A.
    Sandri, A.
    Riccardi, R.
    JOURNAL OF NEURO-ONCOLOGY, 2006, 77 (01) : 89 - 94
  • [16] Temozolomide versus Procarbazine, Lomustine, and Vincristine in Recurrent High-grade Glioma
    Nieder, Carsten
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (05) : 333 - 335
  • [17] Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
    Brada, Michael
    Stenning, Sally
    Gabe, Rhian
    Thompson, Lindsay C.
    Levy, David
    Rampling, Roy
    Erridge, Sara
    Saran, Frank
    Gattamaneni, Rao
    Hopkins, Kirsten
    Beall, Sarah
    Collins, V. Peter
    Lee, Siow-Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4601 - 4608
  • [18] Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
    Zhao, Shuangshuang
    Zhang, Minmin
    Zhang, Qing
    Wu, Jingjun
    Dai, Hui
    BMC CANCER, 2024, 24 (01)
  • [19] Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
    Shuangshuang Zhao
    Minmin Zhang
    Qing Zhang
    Jingjun Wu
    Hui Dai
    BMC Cancer, 24
  • [20] Recurrent High-Grade Glioma
    Eudocia C. Quant
    Jan Drappatz
    Patrick Y. Wen
    Andrew D. Norden
    Current Treatment Options in Neurology, 2010, 12 : 321 - 333
12345